You are here

Award Data

For best search results, use the search terms first and then apply the filters
Reset

The Award database is continually updated throughout the year. As a result, data for FY20 is not expected to be complete until September, 2021.

  1. Development of novel compounds for the treatment of atrial fibrillation

    SBC: Elex Biotech, Inc            Topic: NHLBI

    DESCRIPTION provided by applicant Atrial fibrillation AF is the most prevalent type of cardiac arrhythmia in the developed world affecting million people in the United States alone a number that is expected to double by because of population aging Current pharmacological options are ineffective which may be in part because these drugs fail to target key pathogenic mechanisms Recen ...

    STTR Phase I 2015 Department of Health and Human ServicesNational Institutes of Health
  2. StrikeVEMP: Automated Portable Bone-Conducted Force Stimuli for Recording Acceleration-Produced coVEMPs

    SBC: Ear And Skull Base Center, Inc.            Topic: NIDCD

    DESCRIPTION provided by applicant Each year million Americans go to health care providers because of vertigo dizziness or balance problems It is the second most common complaint heard in doctorandapos s offices and will occur in of the nationandapos s population at sometime in their lives From through of US adults aged years and older million Americans had ve ...

    STTR Phase I 2015 Department of Health and Human ServicesNational Institutes of Health
  3. Preclinical and neuroimmunologic study of RTL1000 for methamphetamine addiction

    SBC: Virogenomics BioDevelopment Inc            Topic: R41

    DESCRIPTION provided by applicant Methamphetamine MA dependence is associated with long term damage to regions of the brain that control cognitive and psychiatric function One third to one half of MA dependent adults experience persistent cognitive and other psychiatric disorders up to three years or longer into remission The neuropsychiatric impairments that persist following abstinence ar ...

    STTR Phase I 2015 Department of Health and Human ServicesNational Institutes of Health
  4. A screening assay for chemicals that affect the differentiation of human neural cells.

    SBC: Nzumbe, Inc.            Topic: NIEHS

    DESCRIPTION provided by applicant Human brain development represents a highly vulnerable time to chemical exposures because immature cells are actively undergoing differentiation into more complex cell types e g neurons astrocytes oligodendroglia to form neural circuits A major reason for this vulnerability is that neuronal differentiation requires critical time dependent changes to the ...

    STTR Phase I 2015 Department of Health and Human ServicesNational Institutes of Health
  5. IMPROVING THE TREATMENT OF CONTAMINATED AQUIFERS BYDEVELOPING DIRECT-PUSH OXIDANT CANDLES WITH PNEUMATIC CIRCULATORS

    SBC: AirLIft Environmental LLC            Topic: NIEHS

    DESCRIPTION provided by applicant Clean water is one of the most basic societal needs in the world Few situations incite more public outcry than when a community learns that their drinking water has been tainted Two of the biggest threats to groundwater quality in the U S are contamination from either chlorinated solvents or petroleum Left unattended the size and scope of the problems asso ...

    STTR Phase II 2015 Department of Health and Human ServicesNational Institutes of Health
  6. Identifying activators of interferon regulatory factors for neuroprotection

    SBC: Neuralexo, LLC            Topic: NINDS

    DESCRIPTION provided by applicant Stroke is a leading cause of morbidity and mortality in the United States However less than of patients are eligible for the current approved interventions of tissue plasminogen activator or thrombectomy We seek to develop new therapeutics to reduce the extent of damage and functional impairment resulting from ischemic injury to the brain an area of signi ...

    STTR Phase I 2015 Department of Health and Human ServicesNational Institutes of Health
  7. Development of Novel Compounds for Treatment of Heart Arrhythmias in CPVT

    SBC: Elex Biotech, Inc            Topic: NHLBI

    DESCRIPTION provided by applicant Abstract Current therapies to treat the orphan disease catecholaminergic polymorphic ventricular tachycardia CPVT have potential side effects so severe that hospitalization is required upon treatment initiation and severely exacerbate depression and fatigue in children that already have psychological issues due to this devastating life long life threaten ...

    STTR Phase II 2015 Department of Health and Human ServicesNational Institutes of Health
  8. Evidenced-based Firefighter Worksite Health and Safety Intervention

    SBC: Odyssey Science Innovations, LLC            Topic: 100

    DESCRIPTION provided by applicant Worksite health promotion is a means to improve employeesandapos lifestyles enhance their wellbeing and increase productivity while reducing healthcare and disability costs However most existing worksite health programs are not evidence based Our company Odyssey Science Innovations LLC was formed by experienced health promotion researchers to take our ...

    STTR Phase II 2015 Department of Health and Human ServicesNational Institutes of Health
  9. Stroke Treatment by Chemically-induced Hypothermia

    SBC: JT Pharmaceuticals, Inc.            Topic: 101

    DESCRIPTION provided by applicant Stroke is a leading cause of human death and disability in the United States while clinical therapy for acute stroke is limited and unsatisfactoy The many failures in clinical trials strongly endorse the idea that to battle this multifaceted bran disorder novel strategies that target multiple cell types and different mechanisms are needed to achieve therapeut ...

    STTR Phase II 2015 Department of Health and Human ServicesNational Institutes of Health
  10. Non-ATP competitive inhibitors of cyclin dependent kinases as cancer therapeutics

    SBC: PPI PHARMACEUTICALS, LLC            Topic: NCI

    DESCRIPTION (provided by applicant): As cancer is one of the leading causes of death in the United States with some sub-types remaining essentially untreatable, expansion of available drug targets will provide significant new options for the development ofmore effective antineoplastic agents. The major goal of this project is to apply a unique drug discovery strategy to cancer drug development. Th ...

    STTR Phase I 2014 Department of Health and Human ServicesNational Institutes of Health
US Flag An Official Website of the United States Government